These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Genetic predictors of cardiovascular disease: the use of chip technology. Cheek DJ; Cesan A J Cardiovasc Nurs; 2003; 18(1):50-6. PubMed ID: 12537090 [TBL] [Abstract][Full Text] [Related]
23. Advances in the development of genetic markers for the diagnosis of disease and drug response. Halapi E; Hakonarson H Expert Rev Mol Diagn; 2002 Sep; 2(5):411-21. PubMed ID: 12271813 [TBL] [Abstract][Full Text] [Related]
25. Common genetic risk factors for coronary artery disease: new opportunities for prevention? Hamrefors V Clin Physiol Funct Imaging; 2017 May; 37(3):243-254. PubMed ID: 26278888 [TBL] [Abstract][Full Text] [Related]
26. [Genetic background of heart failure: SNP association study for heart failure and the underlying diseases]. Ozaki K Rinsho Byori; 2013 Feb; 61(2):167-75. PubMed ID: 23672095 [TBL] [Abstract][Full Text] [Related]
27. Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases. Zaiou M; Benachour H; Marteau JB; Visvikis-Siest S; Siest G Curr Pharm Des; 2009; 15(27):3193-206. PubMed ID: 19754391 [TBL] [Abstract][Full Text] [Related]
28. Clinical applications of whole-genome association studies: future applications at the bedside. Motsinger AA; Ritchie MD; Dobrin SE Expert Rev Mol Diagn; 2006 Jul; 6(4):551-65. PubMed ID: 16824029 [TBL] [Abstract][Full Text] [Related]
29. Recent advances in molecular genetics of cardiovascular disorders. Implications for atherosclerosis and diseases of cellular lipid metabolism. Schmitz G; Aslanidis C; Lackner KJ Pathol Oncol Res; 1998; 4(2):152-60. PubMed ID: 9654602 [TBL] [Abstract][Full Text] [Related]
31. Development of novel cardiovascular therapeutics from small regulatory RNA molecules--an outline of key requirements. Poller W; Fechner H Curr Pharm Des; 2010; 16(20):2252-68. PubMed ID: 20459390 [TBL] [Abstract][Full Text] [Related]
32. A systematic analysis of heart transcriptome highlights divergent cardiovascular disease pathways between animal models and humans. Zhao Y; Sheng Z; Huang J Mol Biosyst; 2012 Feb; 8(2):504-10. PubMed ID: 22159153 [TBL] [Abstract][Full Text] [Related]
33. Serial analysis of gene expression: technical considerations and applications to cardiovascular biology. Patino WD; Mian OY; Hwang PM Circ Res; 2002 Oct; 91(7):565-9. PubMed ID: 12364383 [TBL] [Abstract][Full Text] [Related]
34. Use of genetics and transcriptomics in the diagnosis and treatment of coronary artery disease. Freedman JE; Iafrati HF Rev Esp Cardiol; 2010 Oct; 63(10):1123-6. PubMed ID: 20875351 [No Abstract] [Full Text] [Related]
37. Gene expression profiling in human cardiovascular disease. Steenman M; Lamirault G; Le Meur N; Léger JJ Clin Chem Lab Med; 2005; 43(7):696-701. PubMed ID: 16207127 [TBL] [Abstract][Full Text] [Related]
38. [The role of the -344C/T polymorphism of the aldosterone synthase gene (CYP11B2) in cardiovascular diseases]. Boduła A; Dołyk A; Protasiewicz J; Adamiec R Postepy Hig Med Dosw (Online); 2007 Dec; 61():838-47. PubMed ID: 18202594 [TBL] [Abstract][Full Text] [Related]
39. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Brugts JJ; de Maat MP; Boersma E; Witteman JC; van Duijn C; Uitterlinden AG; Bertrand M; Remme W; Fox K; Ferrari R; Danser AH; Simoons ML; Cardiovasc Drugs Ther; 2009 Apr; 23(2):171-81. PubMed ID: 19082699 [TBL] [Abstract][Full Text] [Related]
40. Cardiovascular pharmacogenetics: on the way toward individually tailored drug therapy. Siffert W Kidney Int Suppl; 2003 May; (84):S168-71. PubMed ID: 12694337 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]